Figure 1. Participant Flow in the Semaglutide Treatment Effect in People With Obesity (STEP) 4 Trial.

^aThese participants received once-weekly semaglutide (safety analysis set).

^bRun-in failures were defined as participants not meeting all 3 randomization criteria: attend the randomization visit, reach the semaglutide maintenance dose of 2.4 mg by week 16 (±3 days), and be receiving semaglutide, 2.4 mg, at week 20.

^cOther reasons are listed in eTable 9 in Supplement 1.

^dOther reasons are listed in eTable 10 in Supplement 1.